GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Infant Bacterial Therapeutics AB (STU:9IB) » Definitions » Tax Provision

Infant Bacterial Therapeutics AB (STU:9IB) Tax Provision : €0.00 Mil (TTM As of Dec. 2024)


View and export this data going back to 2017. Start your Free Trial

What is Infant Bacterial Therapeutics AB Tax Provision?

Infant Bacterial Therapeutics AB's tax provision for the three months ended in Dec. 2024 was €0.00 Mil. Its tax provision for the trailing twelve months (TTM) ended in Dec. 2024 was €0.00 Mil.

Infant Bacterial Therapeutics AB Tax Provision Historical Data

The historical data trend for Infant Bacterial Therapeutics AB's Tax Provision can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Infant Bacterial Therapeutics AB Tax Provision Chart

Infant Bacterial Therapeutics AB Annual Data
Trend Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24
Tax Provision
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - - - -

Infant Bacterial Therapeutics AB Quarterly Data
Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24
Tax Provision Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Infant Bacterial Therapeutics AB Tax Provision Calculation

Tax to be paid.

Tax Provision for the trailing twelve months (TTM) ended in Dec. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was €0.00 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Infant Bacterial Therapeutics AB Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Infant Bacterial Therapeutics AB (STU:9IB) » Definitions » Tax Provision
Comparable Companies
XSAT:HAMLET B OSTO:DMYD B OSTO:MAGLE OSTO:FLUO OSTO:SYNACT OSTO:SANION OSTO:ONCO OSTO:CANTA OSTO:INIT OSTO:IRLAB A VRTX ASX:CSL REGN XKRX:207940 XBRU:ARGX ALNY XBRU:UCB ONC BNTX XKRX:068270
Traded in Other Exchanges
IBT B:Sweden
Address
Bryggargatan 10, Stockholm, SWE, 111 21
Website
https://www.ibtherapeutics.com
Infant Bacterial Therapeutics AB is a pharmaceutical company. Its purpose is to develop and commercialize drugs for diseases affecting premature babies. Its focus is on the drug candidate IBP-9414, whose development program is designed to show a reduced incidence of necrotizing enterocolitis (NEC) and improved gastrointestinal function (SFT) when treated with IBP-9414's active substance Lactobacillus reuteri bacterial strain naturally found in human breast milk. Its portfolio also includes additional drug candidates, IBP-1016, IBP-1118 and IBP-1122. IBP1016, for the treatment of gastroschisis, is a life-threatening and rare disorder in which children are born with externalized gastrointestinal organs.

Infant Bacterial Therapeutics AB Headlines

No Headlines